At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed Mar 31, 2026 at 06:59 ET
Biogen announced the acquisition of Apellis Pharmaceuticals for $41 per share in cash, totaling $5.6 billion in upfront equity consideration, plus a contingent value right (CVR) tied to SYFOVRE® sales milestones. The deal adds two FDA-approved complement-targeting therapies, EMPAVELI® and SYFOVRE®, with combined 2025 revenue of $689 million and expected mid-to-high teens growth through 2028, enhancing Biogen’s immunology and nephrology portfolio.
- Biogen to acquire Apellis for $41 per share in cash, representing an 86% premium to Apellis’s 90-day volume-weighted average price.
- Total upfront equity value is $5.6 billion; additional CVR of up to $4 per share based on SYFOVRE® global net sales milestones ($1.5B and $2B thresholds between 2027–2030, or $2B in 2031).
- EMPAVELI® and SYFOVRE® generated combined net revenue of $689 million in 2025, expected to grow at mid-to-high teens rate at least through 2028.
- Transaction expected to be accretive to Biogen’s non-GAAP EPS starting in 2027 and boost its non-GAAP EPS CAGR through the end of the decade.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access